Left: before statin treatment; right: same patient, one year after statin treatment. Photo: Harvard University
RPB-supported researchers at Massachusetts Eye and Ear/Harvard Medical School and scientists at University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins (cholesterol-lowering medications) for the treatment of patients with the dry form of age-related macular degeneration (AMD) — the leading cause of blindness in the developed world. Although effective treatments are available for the wet form of AMD, they are currently lacking for the more prevalent dry form.
The researchers found evidence that treatment with high-dose atorvastatin (80mg) is associated with regression of lipid deposits and improvement in visual acuity, without progression to advanced disease, in high-risk AMD patients.
February 5, 2016
RPB launches awards in data science and Diabetic Eye Disease.
Leaders of organizations that fund vision research convene in Washington DC to increase collaboration and maximize the impact of research funding for sight-threatening diseases.
An RPB grantee makes a key discovery involving genes that are essential for eye health.
RPB funds a new round of researchers and hits a milestone in supporting vision-related breakthroughs.
We welcome your generosity to help us meet our goal!
Dr. Krzysztof Palczewski develops and applies cutting-edge gene editing techniques to challenging genetic conditions.
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
General Info | Grants | News & Resources |